NextGen Biomed (XTAE:NXGN) Change In Receivables : ₪-0.26 Mil (TTM As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Change In Receivables?

NextGen Biomed's change in receivables for the quarter that ended in Jun. 2023 was ₪-0.31 Mil. It means NextGen Biomed's Accounts Receivable increased by ₪0.31 Mil from Dec. 2022 to Jun. 2023 .

NextGen Biomed's change in receivables for the fiscal year that ended in Dec. 2022 was ₪0.30 Mil. It means NextGen Biomed's Accounts Receivable declined by ₪0.30 Mil from Dec. 2021 to Dec. 2022 .

NextGen Biomed's Accounts Receivable for the quarter that ended in Jun. 2023 was ₪0.32 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NextGen Biomed's liquidation value for the six months ended in Jun. 2023 was ₪-0.08 Mil.

NextGen Biomed Change In Receivables Historical Data

The historical data trend for NextGen Biomed's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Change In Receivables Chart

NextGen Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.01

0.03

-0.17

-0.10

0.30

NextGen Biomed Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial													0.02	-0.12	0.25	0.05	-0.31

NextGen Biomed Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-0.26 Mil.

NextGen Biomed (XTAE:NXGN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NextGen Biomed's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.319	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, NextGen Biomed's accounts receivable are only considered to be worth 75% of book value:

NextGen Biomed's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.343	-	2.659	+	0.75 * 0.319	+	0.5 * 0
=	-0.08

NextGen Biomed Change In Receivables Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NextGen Biomed (XTAE:NXGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101

Website

http://www.nextgen-biomed.com

NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.